Olumiant® ▼ (baricitinib)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Olumiant Summary of Product Characteristics (SmPC)

Olumiant® ▼ (baricitinib): Use in Patients with a History of Malignancy

Baricitinib (BARI) was not systematically studied in patients with moderate to severe RA and malignant disease.

Information from the label

The risk of malignancies including lymphoma is increased in patients with rheumatoid arthritis. Immunomodulatory medicinal products may increase the risk of malignancies including lymphoma. The clinical data are insufficient to assess the potential incidence of malignancies following exposure to baricitinib. Long-term safety evaluations are ongoing.1

Clinical Trial Criteria

Patients with a history of malignancy were not uniformly excluded from the BARI phase 3 clinical development program.2

Patients who were able to participate in the BARI phase 3 clinical trials included patients with

  • cervical carcinoma in situ that had been resected with no evidence of recurrence or metastatic disease for at least 3 years, and

  • basal cell or squamous epithelial skin cancers that had been completely resected with no evidence of recurrence for at least 3 years.2

However, patients were excluded from the phase 3 trials if they had

  • a history of lymphoproliferative disease

  • signs or symptoms suggestive of possible lymphoproliferative disease, including lymphadenopathy or splenomegaly

  • active primary or recurrent malignant disease, or

  • been in remission from clinically significant malignancy for <5 years.2

Baricitinib Phase 3 Program

Each of the 4 phase 3 studies in the clinical program evaluated a distinct treatment population of patients with moderate-to-severe RA.

  • RA-BEGIN compared BARI 4 mg monotherapy, BARI 4 mg plus MTX, and MTX monotherapy in patients who had limited or no prior treatment with MTX and were naïve to other DMARDs.3

  • RA-BEAM compared BARI 4 mg vs placebo or adalimumab, with background MTX, in patients with inadequate response to MTX.4 

  • RA-BUILD compared BARI 2 mg and 4 mg vs placebo, with background csDMARD therapy, in patients with inadequate response to csDMARDs.5

  • RA-BEACON compared BARI 2 mg and 4 mg vs placebo, with background csDMARD therapy, in patients with an inadequate response to at least one TNF inhibitor, who may also have had an inadequate response to one or more non-TNF inhibitor biologic DMARDs.6

Patients With Medical History of Malignancy in the Baricitinib Phase 3 Program

Medical history, including malignancy, was recorded upon enrollment into each of the BARI phase 3 clinical studies.

A history of malignancy was defined as malignancy that was previously diagnosed and resolved prior to study entry.

As shown in Table 1. Comorbid Conditions of Special Interest in the Baricitinib Phase 3 Studies , the number of patients who had a historical diagnosis of malignancy at baseline included

  • 1.8% (12/684) in RA-BUILD

  • 2.1% (11/527) in RA-BEACON

  • 1.3% (17/1305) in RA-BEAM, and

  • 2.2% (13/584) in RA-BEGIN.2

Patients With Preexisting Malignancy in the Baricitinib Phase 3 Program

A preexisting malignancy was defined as malignancy that was previously diagnosed and was ongoing at study entry.2

In RA-BEGIN, 1 patient (0.2%) in the MTX treatment group reported preexisting malignant tumors and skin neoplasms at enrollment Table 1. Comorbid Conditions of Special Interest in the Baricitinib Phase 3 Studies .2

Efficacy and Safety Analysis of Patients With a History of Malignancy

The individual phase 3 clinical trials were not designed to detect differences in the efficacy and safety of BARI for the treatment of moderate to severe RA in patients with or without a medical history or pre-existing condition of malignancy. Due to the small numbers of patients with a medical history or preexisting condition of malignancy in the BARI phase 3 clinical program for RA, an analysis of the efficacy and safety of BARI in these patients is not feasible.

Table 1. Comorbid Conditions of Special Interest in the Baricitinib Phase 3 Studies2

 

RA-BUILD

(N=684)

RA-BEACON

(N=527)

RA-BEAM

(N=1305)

RA-BEGIN

(N=584)

Selected preexisting conditions (mITT)

Malignancies, n (%)

0 (0.0)

0 (0.0)

0 (0.0)

1 (0.2)

Selected historical diagnoses (mITT)

Malignancies, n (%)

12 (1.8)

11 (2.1)

17 (1.3)

13 (2.2)

Abbreviations: mITT = modified intent-to-treat. 
Percentages are based on the number of patients in the analysis.

References

1. Olumiant [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

2. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

3. Fleischmann R, Schiff M, van der Heijde D, et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol. 2017;69(3):506-517. http://dx.doi.org/10.1002/art.39953

4. Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376(7):652-662. http://dx.doi.org/10.1056/NEJMoa1608345

5. Dougados M, van der Heijde D, Chen YC, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study [published correction appears in Ann Rheum Dis. 2017;76(9):1634. http://dx.doi.org/10.1136/annrheumdis-2016-210094corr1 ]. Ann Rheum Dis. 2017;76(1):88-95. http://dx.doi.org/10.1136/annrheumdis-2016-210094

6. Genovese MC, Kremer J, Zamani O, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016;374(13):1243-1252. http://dx.doi.org/10.1056/NEJMoa1507247

Glossary

BARI = baricitinib

csDMARD = conventional synthetic disease-modifying antirheumatic drug

DMARD = disease-modifying antirheumatic drug

MTX = methotrexate

PBO = placebo

RA = rheumatoid arthritis

TNF = tumor necrosis factor

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Date of Last Review: May 13, 2019

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 8am - 4pm, excluding Bank Holidays

Or you can

Ask us a question Chat with Us If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a question